Modified Vaccine for High Risk or Low Residual Melanoma Patients

This study is designed for patients who had malignant melanoma and, following tumor removal, are now free of disease, or have only very minor residual disease, and are at a very high risk of disease recurrence. These patients will be treated with the A2/4-1BBL melanoma vaccine, a compatible melanoma cell line that has been engineered to express a molecule termed 4-1BBL, which enhances the chances of the cell line to be recognized by the patient's immune system, and to induce its stimulation. The hypothesis that drives the study states that the immune response against the cell line will also be

Trial Details

NCT ID
NCT01898039
Phase
PHASE1 / PHASE2
Sponsor
Hadassah Medical Organization
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • A2/4-1BBL melanoma vaccine
  • DNP sensititzation
  • Cyclophosphamide
Locations (sample)
  • Jerusalem, Israel|31.76904,35.21633

Key Eligibility Criteria

  • Patients included in this protocol must carry one or more of the following tissue typing alleles: HLA-A2, -A24, -A33, -B35, -B49, -CW04/12(04/08). …
  • Cutaneous malignant melanoma AJCC stage IIb (\>4 mm) or IIc (ulcerated melanoma \>4mm).
  • Metastatic melanoma AJCC stage III (nodal involvement, N1-3a,b) post-surgical removal of lymph nodes.
  • Metastatic melanoma AJCC stage IV, completely resected.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →